Effects of SGLT2 Inhibition in Human Kidney Proximal Tubular Cells—Renoprotection in Diabetic Nephropathy?

Panchapakesan, Usha; Pegg, Kate; Gross, Simon; Komala, Muralikrishna Gangadharan; Mudaliar, Harshini; Forbes, Josephine; Pollock, Carol; Mather, Amanda
February 2013
PLoS ONE;Feb2013, Vol. 8 Issue 2, p1
Academic Journal
Sodium/glucose cotransporter 2 (SGLT2) inhibitors are oral hypoglycemic agents used to treat patients with diabetes mellitus. SGLT2 inhibitors block reabsorption of filtered glucose by inhibiting SGLT2, the primary glucose transporter in the proximal tubular cell (PTC), leading to glycosuria and lowering of serum glucose. We examined the renoprotective effects of the SGLT2 inhibitor empagliflozin to determine whether blocking glucose entry into the kidney PTCs reduced the inflammatory and fibrotic responses of the cell to high glucose. We used an in vitro model of human PTCs. HK2 cells (human kidney PTC line) were exposed to control 5 mM, high glucose (HG) 30 mM or the profibrotic cytokine transforming growth factor beta (TGFβ1; 0.5 ng/ml) in the presence and absence of empagliflozin for up to 72 h. SGLT1 and 2 expression and various inflammatory/fibrotic markers were assessed. A chromatin immunoprecipitation assay was used to determine the binding of phosphorylated smad3 to the promoter region of the SGLT2 gene. Our data showed that TGFβ1 but not HG increased SGLT2 expression and this occurred via phosphorylated smad3. HG induced expression of Toll-like receptor-4, increased nuclear deoxyribonucleic acid binding for nuclear factor kappa B (NF-κB) and activator protein 1, induced collagen IV expression as well as interleukin-6 secretion all of which were attenuated with empagliflozin. Empagliflozin did not reduce high mobility group box protein 1 induced NF-κB suggesting that its effect is specifically related to a reduction in glycotoxicity. SGLT1 and GLUT2 expression was not significantly altered with HG or empagliflozin. In conclusion, empagliflozin reduces HG induced inflammatory and fibrotic markers by blocking glucose transport and did not induce a compensatory increase in SGLT1/GLUT2 expression. Although HG itself does not regulate SGLT2 expression in our model, TGFβ increases SGLT2 expression through phosphorylated smad3.


Related Articles

  • The Side Effects of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor. Won Jin Kim; Sang Soo Kim // Journal of Korean Diabetes;2014, Vol. 15 Issue 3, p158 

    Anti-diabetic drugs for effectively lowering glucose with limited side effects are necessary in providing patientcentered diabetic management. Sodium glucose cotransporter 2 (SGLT 2) inhibitors provide a novel therapeutic approach for managing type 2 diabetic patients by lowering glucose levels...

  • The Effect of Telmisartan on Selected Plasma Adipoeytokines and their Expressions in Subcutaneous Adipose Tissue in Patients with High Risk of Diabetes. Wohl, Petr; Krušinová, Eva; Kratochvílová, Simona; Kopecky, Jan; Komers, Radko; Pelikáová, Terezie // Diabetes;Jun2007 Supplement 1, Vol. 56, pA513 

    Recently it has been shown, that telmisartan can activate PPARγ and increase the expression of PPARγ target genes known to be involved in the regulation of lipid and glucose metabolism. The aim of our study was to test the effect of telmisartan on free fatty acids (FFA) and selected...

  • Induction of B1 receptors in streptozotocin diabetic rats: possible involvement in the control of hyperglycemia-induced glomerular Erk 1 and 2 phosphorylation. Mage, Marilyne; Pecher, Christiane; Neau, Eric; Cellier, Eric; Dos Reiss, Marina L.; Schanstra, Joost P.; Couture, Rejean; Bascands, Jean-Loup; Girolami, Jean-Pierre // Canadian Journal of Physiology & Pharmacology;Apr2002, Vol. 80 Issue 4, p326 

    We investigated the effects of a 3-week treatment with various combinations of angiotensin-converting enzyme inhibitor (ACEI) and B[sub1] and B[sub2] bradykinin receptor (B[sub1] R and B[sub2] R) antagonists (B[sub1] A and B[sub2] A) and AT1 receptor antagonist on ERK 1 and 2 phosphorylation in...

  • DPP-4 inhibitors: First evidence for use in T1D? Scott, Adrian // Diabetes Digest;2012, Vol. 11 Issue 1, p15 

    The article focuses on the glucagon-like peptide-1 (GLP-1) which is used to look for the difference of type 1 diabetes (T1D) and type 2 diabetes (T2D), wherein it is less obvious on a person with T2D.

  • TRADJENTA.  // Nurse Practitioners Prescribing Reference;Fall2011, Vol. 18 Issue 3, pA-11 

    The article offers brief information on the Linagliptin tablet from Boehringer Ingelheim and Lilly.

  • How incretin-based therapies address the spectrum of physiologic disturbance in type 2 diabetes. Deter, D. M. // Internet Journal of Academic Physician Assistants;2010, Vol. 8 Issue 1, p1 

    The article focuses on the use of incretin-based therapies in the management of type 2 diabetes. It is stated that glucagon-like-peptide 1 (GLP-1) secretion may be reduced in type 2 diabetes, and intravenous replacement improves glucose homeostasis. Due to the glucose-dependent insulin-secreting...

  • No better than cheaper drugs. Perry, Thomas L.; Lippman, Stephen S.; McConnell, Mark; Tejani, Aaron M. // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;4/28/2012, Vol. 344 Issue 7854, p27 

    A letter to the editor is presented in response to the article "Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis" by Thomas Karagiannis and colleagues in the March 12, 2012 issue.

  • Omarigliptin: First Global Approval. Burness, Celeste // Drugs;Nov2015, Vol. 75 Issue 16, p1947 

    Omarigliptin [Marizev (Japan)] is a small-molecule dipeptidyl peptidase-4 (DPP-4) inhibitor developed by Merck for the oral treatment of type 2 diabetes (T2DM). Unlike the majority of other approved agents of its class, which are usually administered once daily, omarigliptin can be administered...

  • Dipeptidyl Peptidase 4: A New Link between Diabetes Mellitus and Atherosclerosis? Silva Júnior, Wellington Santana da; Godoy-Matos, Amélio Fernando de; Kraemer-Aguiar, Luiz Guilherme // BioMed Research International;6/4/2015, Vol. 2015, p1 

    Type 2 diabetes mellitus (T2DM) has become one of the most prevalent noncommunicable diseases in the past years. It is undoubtedly associated with atherosclerosis and increased risk for cardiovascular diseases. Incretins, which are intestinal peptides secreted during digestion, are able to...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics